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Abstract Until now, models of psychiatric diseases have
typically been animal models. Whether they were to be
used to further understand the pathophysiology of the
disorder, or as drug discovery tools, animal models have
been the choice of preference in mimicking psychiatric
disorders in an experimental setting. While there have
been cellular models, they have generally been lacking
in validity. This situation is changing with the advent of
patient-specific induced pluripotent stem cells (iPSCs).
In this article, we give a methodological evaluation of
the current state of the iPS technology with reference to
our own work in generating patient-specific iPSCs for
the study of autistic spectrum disorder (ASD). In addi-
tion, we will give a broader perspective on the validity of
this technology and to what extent it can be expected to
complement animal models of ASD in the coming years.
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Introduction
Autistic spectrum disorder (ASD) is a complex and heteroge-
neous early onset neurodevelopmental condition characterized
by profound impairments in social and language skills and by
stereotypical behaviours. ASD has a substantial and complex
underlying genetic component (Devlin and Scherer 2012)with
more than 100 genes implicated in the aetiology, none ofwhich
alone account for more than 2 % of cases (Betancur 2011).
Furthermore, single gene defects, CNVs and syndromic forms
account for only 10–20% of cases (Betancur 2011). This com-
plex genetic heterogeneity overlapping as it does with other
conditions such as severe intellectual impairment and epilepsy
(Devlin and Scherer 2012) and combined with a lack of other
diagnosticbiomarkersmeans thatASD is still clinicallydefined
bybehavioural assessments (Lord et al. 1989; Lord et al. 1994).
In this respect, considerable work has gone into developing
animal models of ASD in terms of defining behavioural assays
reflecting the core symptoms of the disorder: social interaction,
communicationandrepetitivebehaviours (Crawley2012).Fur-
thermore,anincreasingcatalogueofgenesassociatedwithASD
has been replicated in transgenic models, and environmental
factors implicated in the disorder, such as prenatal exposure to
valproate, have been successfully shown to produce ASD-like
symptoms in mice according to these behavioural assays
(Roullet et al. 2013). However, drug discovery for psychiatric
disorders generallyhas faced seriousproblems, largelyemanat-
ingfromthefailureofthepredictivevalidityofanimalmodelsof
disease (Markou et al. 2009; van der Worp et al. 2010). Drug
discoveryinthisareahasthereforebeenslow,andalthoughthere
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are somerecent additions to thepipeline for syndromic formsof
ASD (Krueger and Bear 2011; Hampson et al. 2012), there is
currentlynotasingleapprovedtreatmentforASDinJapanorthe
five major European jurisdictions, and only risperidone and
aripiprazole, two atypical antipsychotics, are approved in the
US for themanagement of irritability (Nightingale 2012).
Studies in vitro using either rodent primary neurons or
immortalized cell lines over-expressing a molecular target of
interest have been and will continue to be valuable in high-
throughput screening in the drug discovery process (Eglen
and Reisine 2011). However, these systems also have ques-
tionable validity either by virtue of simply being non-human
or from artefacts of over-expression. A significant advance
in the generation of more physiologically relevant cell types
came from the successful isolation and culture of human
embryonic stem cells (hES) (Thomson et al. 1998). Within
the context of psychiatric disorders, this permitted for the
first time the possibility of generating human neurons in vitro
and protocols have since been developed to generate a num-
ber of different neuronal subtypes by directed differentiation
with morphogens along known developmental trajectories
(Muguruma et al. 2010). However, in addition to ethical
concerns with hES generation, modelling diseases with re-
duced penetrance or complex genetics in hES cells is still not
straightforward. Work towards developing embryonic stem
(ES) cells from interspecies human/animal hybrid embryos
attempted to overcome the latter issue but faced additional
ethical concerns and legislative barriers (St John et al. 2008)
and are technically cumbersome to deliver.
As a consequence of the groundbreaking work of the
Yamanaka lab, somatic cells can now be reprogrammed
into pluripotent stem cells from a simple patient biopsy
(typically skin, blood or hair) (Takahashi and Yamanaka
2006; Takahashi et al. 2007). This technology therefore
allows the delivery of human neurons in vitro, derived
precisely from patients suffering from a specific disor-
der. Where that disorder is neurodevelopmental, with a
strong genetic component such as ASD, then this be-
comes an attractive technology since it allows us to
recapitulate in a culture dish precisely those develop-
mental events that are putatively abnormal during the
aetiology of the disorder (Marchetto and Gage 2012).
These patient-specific induced pluripotent stem cells
(iPSCs) present several important advantages over other
in vitro systems. The derived cells are human yet do not
have the accompanying ethical issues surrounding hu-
man ES cells. Furthermore, given that none of the genes
implicated in ASD are fully penetrant for the condition,
the influence of genetic background is problematic for
approaches to modelling ASD in vitro where mutations
are engineered into pre-existing pluripotent human cell
lines. Patient-specific iPSCs represent a powerful new
approach to capture both the primary genetic lesion and
the genetic background from human individuals with con-
firmed diagnoses of ASD. Furthermore, it facilitates the study
of larger deletions in complex genes containing internal pro-
moters or polygenic cases which are currently difficult to
engineer using genome editing technologies.
In addition to providing a methodological perspective
on the iPSC technology, this review will seek to identify
where patient-specific iPSCs can be expected to comple-
ment animal models in identifying disease mechanisms in
ASD as part of the early stages of the drug discovery
process. It is clear however that this technology is not
limited to this stage of the drug discovery process, and
iPSCs and their differentiated derivatives are increasingly
being used in the development of assays for the screening
of compound libraries to identify disease modifying drugs
(Yang et al. 2013) and the development of more sophis-
ticated in vitro toxicology assays (Anson et al. 2011). It
has even been suggested that iPSCs could be generated
from participants of clinical trials to interrogate how in-
dividual genetic variation affects drug responses and con-
ceivably also to test new compounds in ‘in vitro clinical
trials’ (Eglen and Reisine 2011).
Technical issues in the generation of iPSC lines
The initial approach to generating iPSCs used fibroblasts
as the starting material (Takahashi and Yamanaka 2006;
Takahashi et al. 2007). This cell type is accessible by skin
biopsy but is invasive and may be considered unsuitable
for young children. iPSCs have also been successfully
derived from other accessible tissue types including blood
and hair keratinocytes (Ye et al. 2009; Aasen et al. 2008).
However, although obtaining blood is a routine procedure,
it can be difficult to perform on severely autistic children
without distress. A promising alternative cell type is
keratinocytes derived from the root shaft of scalp hair
(Aasen et al. 2008; Aasen and Izpisúa Belmonte 2010).
This is a relatively non-invasive procedure and sufficient
keratinocytes can be generated from a single hair to gen-
erate iPS cell lines (Fig. 1.). Furthermore, we have found
that it is possible to maintain viable hair samples for at
least 48 h at ambient temperatures in media containing
10 % foetal bovine serum buffered with 15 mM HEPES
before plating. This allows for considerable flexibility in
sample acquisition and transport.
The first group to derive iPSCs from keratinocytes report-
ed that the kinetics and efficiency of reprogramming were
substantially increased over that of fibroblasts (Aasen et al.
2008). In our study, switching keratinocytes to ES media 2 or
3 days after transduction with the reprogramming vector gives
a very low efficiency of reprogramming (<0.001 %), possibly
due to elevated calcium-driving terminal differentiation of the
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keratinocytes before sufficient reprogramming has occurred
(Hennings et al. 1980). We have adopted a protocol similar to
that of Zhu et al. (2010) in which keratinocytes, after being
transduced with the reprogramming vector, are maintained for
an extended period in low calcium serum-free keratinocyte
growth media before being adapted to hES media. Using this
approach, we observe a similar efficiency of reprogramming
to fibroblasts (∼0.05 %), but with slightly faster kinetics
(colonies are ready to transfer into feeder-free conditions after
21 days). The lower reprogramming efficiency we observe in
keratinocytes compared to the original report (Aasen et al.
2008) has also been observed by others (Carey et al. 2009) and
could be due to a number of factors including the titre of virus
used and the nature of the reprogramming construct. Rather
than individual retroviral vectors for the four reprogramming
factors, we use a polycistronic lentiviral construct flanked
with loxp sites at an MOI of two to increase the likelihood
of deriving lines with single integrands, thus allowing easier
removal of the vector, and decreasing the risk of insertional
mutagenesis (Papapetrou and Sadelain 2011). However, it
should be noted that the iPS field is increasingly moving
towards the use of non-integrating systems such as Sendai
virus (Nishimura et al. 2011), episomal (Yu et al. 2009) and
modified RNA vectors (Warren et al. 2010).
Validation of iPSC pluripotency and quality control
There is no universally agreed set of criteria in the field for
demonstration of pluripotency in hiPSCs, although attempts
have begun to work towards such a goal (Maherali and
Hochedlinger 2008; Daley et al. 2009). Nevertheless, vari-
ous assays to assess pluripotency have been developed and
are essential for the quality control of newly derived iPS
lines. These include immunocytochemical and quantitative
PCR (qPCR) analysis of markers either associated with or
necessary for the maintenance of the pluripotent state. We
routinely assess lines for Oct4, Nanog, Tra1-81 and SSEA4
(Fig. 2a). The expression of alkaline phosphatase is also
associated with pluripotency (Andrews et al. 1984) and is
assessed by a colorimetric assay of enzymatic activity on
lightly fixed cells (Fig. 2a (iv)).
The teratoma assay has generally been considered the gold
standard for demonstrating pluripotency in humanESor iPSCs
(MaheraliandHochedlinger2008;Daleyetal.2009).However,
anumberof serious shortcomingshavebeen identifiedwith this
assay including an absence of agreedobjectiveminimal criteria
forassessingandreportingteratomas(Mülleretal.2010)andthe
reported failure of this assay to robustly distinguish between
partiallyandmorefullyreprogrammediPSCs(Chanetal.2009).
Fig. 1 Derivation of keratinocytes from scalp hair. The root shaft of
each hair was plated onto matrigel-coated dishes, a presoaked coverslip
placed over the top of the dissected hair root, and mouse embryonic
fibroblast-conditioned media with 50 μg/ml gentamicin was added to
each well. Once the keratinocytes had begun to migrate from the hair
shaft onto the matrigel substrate, the media was switched to Epilife with
EDGS supplement (Life Technologies), and the gentamicin was re-
moved. For subsequent passaging, keratinocytes were pretreated for
1 h with Y-27632 (10 μM) before being dissociated with Accutase and
plating onto type I collagen-coated plates in keratinocyte media (with
Y27632 (10 μM) for the first 24 h)
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Alternative methods that are more quantitative and higher
throughput are being developed, such as the array based bioin-
formatics approach developed by the Loring lab (Müller et al.
2011).Weusethismethod(Fig.2b)complementedbyaninvitro
assessment of spontaneous differentiation into the three germ
layers fromembryoid bodies (Fig. 2c).
In addition to pluripotency, it is also essential to
demonstrate genomic stability in the iPS line. This is
routinely performed by generating a G-banded karyo-
type (Fig. 2d). Although a more detailed appraisal of
structural abnormalities within chromosomes can be
attained by the use of comparative genomic hybridiza-
tion arrays, this approach cannot completely substitute
for karyotyping as the former will not detect balanced
translocations or inversions.
We also routinely assess each new iPS line for the capac-
ity to fully neutralise in adherent culture to ensure consis-
tency in down-stream assays. The addition of SMAD in-
hibitors to iPSCs plated at high density in a neural mainte-
nance media should form a uniform layer of Pax6+ve
neuroepithelial cells (Fig. 3a) (Chambers et al. 2009; Shi
et al. 2012). Upon passaging these neuroepithelial cells, a
uniform field of neural rosettes should form (Fig. 3b). In the
absence of additional patterning factors, these rosettes
should then generate neuronal subtypes of the dorsal telen-
cephalon (Fig. 3c).
Fig. 2 Representative images for the validation of iPSC pluripotency
and quality control. aUndifferentiated iPSCs were probed with primary
antibodies to Oct4, Nanog, SSEA4 and Tra1-81 and assessed for alka-
line phosphatase enzymatic activity. b To assess the capacity of the iPS
lines to spontaneously differentiate into the three embryonic lineages,
EBs were generated in vitro for 2 days and then plated onto gelatin-
coated plates. The cultures were grown for a further 12 days before
fixing and staining for mesodermal, endodermal and neuroectodermal
markers Brachyury, Nkx2.5 and β-iii-tubulin, respectively. c For the
assessment of pluripotency using ‘PluriTest’, total RNA was extracted
from iPS cells and genome wide gene expression analysis was
performed on Illumina HT12v4 beadchips at the Genome Centre,
Queen Mary, University of London. For Pluritest analysis, intensity
data files were uploaded at http://www.pluritest.org and analysis
performed according to Muller et al. (2011). d Karyotypes were gener-
ated from 70–80 % confluent cells treated with 100 ng/ml colcemid
(Life Technologies) for 3 h and subjected to hypotonic lysis in 0.075 M
potassium chloride for 10 min at 37 °C. Samples were then fixed in
methanol/glacial acetic acid (ratio 3:1) and stained with Giemsa on
glass slides for analysis. Twenty metaphase cells were counted for each
line and four cells analysed in detail
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Selection of ASD subgroups for the generation of iPSCs
and anticipated cellular phenotypes
Just as with animal models, capturing the heterogeneity of
disorders such as autism in cellular models presents a chal-
lenge. There are several aspects to heterogeneity: clinical,
genetic and phenotypic. From an iPS standpoint, the genetic
heterogeneity is the most readily addressed and will probably
be the starting point for analysis in a number of laboratories.
Research groups will gravitate towards specific genetic le-
sions, hoping that the phenotypes that emerge will have gen-
eral relevance, but the genetic heterogeneity of ASD and its
varying severity between individuals will ultimately require
the derivation and comparison of patient specific iPSCs from
large numbers of individuals.
In our own studies, we have chosen in the first instance to
focus on a subset of ASD individuals at the extreme end of the
spectrum who have a clear genetic lesion in a gene that has a
strong association with the disorder. This limits the degree to
which it may be possible to make more general comments
about ASD based on any initial findings but should increase
the signal-to-noise ratio that will undoubtedly be problematic
in looking for phenotypes in the wider ASD population.
However, any phenotype observed can then be investigated
in additional ASD subgroups.
We have generated iPSCs from individuals with deletions
in the gene SHANK3 who have been diagnosed with ASD.
This includes an individual with an interstitial deletion
extending from the third intron of SHANK3 to beyond the
end of the gene (Fig. 4).
This deletion encompasses all of themajor protein interaction
domainsof thegeneproduct and leaves the individual effectively
hemizygous for SHANK3. Deletions in SHANK3 are strongly
associatedwithASD(Jeffrieset al. 2005;Durandet al. 2007) and
have been shown to be critical in the neurological disorder
Phelan–McDermid syndrome which itself has a strong associa-
tion with ASD (>50 %) (Bonaglia et al. 2001; Phelan and
McDermid 2012). SHANK3 plays a central role in the post-
synaptic density (PSD) of glutamatergic synapses acting as a
scaffolding protein for receptors and the actin cytoskeleton
(Verpelli etal.2012).WithinthePSD,SHANK3formsatetramer
withHomerwhichinturngeneratesahigherorderlatticestructure
that links to the actin cytoskeleton and plays an important role in
stabilizing the structure of the dendritic spine (Hayashi et al.
2009). Studies in which SHANK3 gene dosage have been re-
duced in primary neuronal cultures by siRNA have shown re-
ductions in dendritic spine density (Roussignol et al. 2005;
Verpelli et al. 2011). Conversely, overexpression of SHANK3
in aspiny cerebellar neurons was shown to be sufficient to
induce dendritic spine formation (Roussignol et al. 2005).
Overexpression of SHANK3 constructs containing truncating
mutations found in individualswithASDhas also been found to
have a dominant-negative effect on spine induction andmatura-
tion inprimaryneuronalcultures (Durandetal.2012). Inaddition
to effects on the morphology and number of spines, more subtle
effects have been observed on the functional connectivity of
dendritic spines where SHANK3 gene-dosage is reduced. Most
strikinglyperhaps is a specific reduction reported inmGluR5and
in activity-dependent long-termdepression (Verpelli et al. 2011).
These insights gained into the role of SHANK3 in synapse for-
mation and stability have come in the most part from studies in
primary rodent cells. Such studies could undoubtedly be under-
taken in human iPSCs, but in addition to providing a human
context for such work, iPSCs will also allow for the study of
developmental aspects of neurobiology that are not possible in
terminally differentiated primary neurons and are impractical in
animalmodels.Forexample, it isnot clear thata simple reduction
in gene dosage of the full length transcript is responsible in all
cases of ASD associated with mutations in SHANK3. The
SHANK3 gene has a complex transcriptional profile with both
alternatively spliced exons and intragenic promoters (Maunakea
et al. 2010;Wilson et al. 2003). The heterogeneity in the clinical
presentation of individualswithmutations andmicrodeletions in
different regions of the SHANK3 gene is possibly due to differ-
ential effects of isoformdosage. Indeed, variable phenotypes are
observedinthefivedifferentlinesofmicethathavebeenreported,
Fig. 3 Neuralisation of iPSCs was differentiated at high density in
monolayer culture in the presence of SMAD inhibitors. a Uniform
PAX6 staining of early neuroepithelial cells. b Rosette formation by
neural progenitors after passaging of neuroepithelial cells. The apical
lumen of the rosette is stained with the tight junction protein ZO-1,
whilst acetylated tubulin forms a radial structure from the lumen out-
wards. c Early passaging and differentiation of these neural progenitors
with the NOTCH inhibitor DAPT give rise to large numbers of TBR1/
β-iii-tubulin+ve putative layer VI cortical neurons
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carrying different truncating mutations in the SHANK3 gene as
models of ASD (Jiang and Ehlers 2013, for review). Clarifying
the role of so many isoforms in neuronal development, synapse
formation,stabilizationandplasticitywithinthecontextofanimal
models ofASDwill clearly be a formidable task. The capacity to
generate differentiated human neurons from iPSCs following a
default developmental trajectory offers a much more tractable
approachtoexaminingtheroleofSHANK3isoformsinneuronal
development, synaptogenesis and plasticity. The most relevant
findings in vitro can then be examined in animal models to
determine the behavioural consequences and responses to phar-
macological interventions based on those isoformdifferences.
Selection of cell types for analysis
Our current understanding of the function ofmany of the genes
associated with autism directs us towards the glutamatergic
synapse (Ebert and Greenberg 2013), but of course, there is no
guarantee that the ‘autistic phenotype’ entirely resides there.
Many of the ‘synaptic’ genes that are implicated in ASD have
broad expression patterns. SHANK proteins, for example, are
expressedinthethymusandgutendothelium,aswellasthebrain
(Redecker et al. 2006; Huett et al. 2009). It may be no coinci-
dence that autistic patients typically have gastrointestinal
comorbidities and that the disorder is thought bymany to have
an immunological component (Buie et al. 2010;McAllister and
Patterson 2012). Even if we accept that within the brain we are
indeed looking for a glutamatergic synaptic phenotype, the
question arises—which neuronal subtypes are most affected
and from which regions of the brain? A relatively consistent
finding inASDneuropathologyis reducedminicolumnspacing
and neuronal density in the prefrontal cortex (Casanova et al.
2002; Buxhoeveden et al. 2006; Casanova et al. 2010).A num-
ber of robust protocols exist for the differentiation of human
iPSCsandEScells intorostrodorsalcorticalneuronseitherfrom
embryoid bodies (Pankratz et al. 2007) or in adherent culture
usingSMADpathwayinhibitors(Chambersetal.2009;Shietal.
2012). Interestingly, the sequential production of infragranular
to supergranular cortical neuronal subtypes is recapitulated in
these in vitro systems (Eiraku et al. 2008; Shi et al. 2012).
Another of the more consistent findings reported in post-
mortem studies of ASD brains is cell loss in the Purkinje layer
of the cerebellum (Ritvo et al. 1986; Bailey et al. 1998; Palmen
et al. 2004; Whitney et al. 2008). However, it is also clear from
these studies that this is not an invariable feature of autism and
it is yet unclear if this represents etiologically distinct subgroups
of ASD. The effects on Purkinje neurons of knocking-out
SHANK3 in animal models of ASD are unlikely to be infor-
mative in this respect as it have been shown that, although in the
mouse cerebellum, the expression of SHANK3 is highly
expressed in the granule cell layer it is barely detectable in the
Fig. 4 Diagram of the extent of the genetic lesion in the gene SHANK3
in an autistic individual. A 4-year-old boy with absent speech, devel-
opmental delay and a confirmed diagnosis of autism was found to have
a deletion of the gene SHANK3 on chromosome 22q by comparative
genomic hybridization array. The deletion extends from the third intron
of SHANK3 to beyond the end of the gene
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Purkinje cell layer (Verpelli et al. 2012). Interestingly, however,
we have found that the expression pattern of SHANK3 in
human brain displays the opposite pattern such that the expres-
sion is high in Purkinje cells and undetectable in the granule
cell layer (Fig. 5).
This is a clear example of where animal models could lead to
misleading findings, and a human neuronal model would prove
valuable. Indeed, a striking overlap in the synaptic pathophys-
iology in Purkinje cells observed between syndromic (Fragile
X) and non-syndromic (Neuroligin-3 knock-out) mouse
models of ASD is unlikely to be recapitulated in a SHANK3
knock-out mouse model for this reason (Baudouin et al. 2012).
However, although at present, there are reports of deriving both
cerebellar granule and Purkinje cell neurons from mouse ES
cells (Su et al. 2006; Muguruma et al. 2010), it is unknown if
similar induction protocols will efficiently generate these neu-
ronal subtypes from human iPSCs. Indeed, some other poten-
tial sites for autism pathology have not yet been addressed in
iPSCs, neurons of the amygdala, for example (Baron-Cohen
2000), but there seems no reason in principle why such proto-
cols could not be developed.
A more fundamental limitation might lie around the issue
of cell autonomous versus system phenotypes. We have no
right at the moment to assume that autism has a simple cellular
phenotype. The clinical features of autism—social behaviour,
language and repetitive behaviours—do not reside in a single
cell type. They are emergent properties of brain systems. Even
the anatomical features of the disease will not necessarily be
reducible to a simple cellular phenotype. Alterations in brain
volume, for example, have been documented in a number of
imaging and post-mortem studies of ASD. There has been a
consistent finding of brain overgrowth in ASD beginning
around the age of 1 year, levelling off by 3 years, and possibly
followed by a decline in later life (Redcay and Courchesne
2005). Interestingly, however, this early overgrowth is not
uniform across the brain and is most apparent in the frontal
cortex, amygdala and cerebellum (Carper et al. 2002; Sparks
et al. 2002; Courchesne et al. 2001). The neuropathological
findings that are evident upon closer cytological examination
in these regions could conceivably be reducible to cellular
phenotypes, but not necessarily so.
However, of the studies published so far using iPSCs to
discover cellular phenotypes associated with psychiatric dis-
ease, the data are encouraging. For example, Brennand et al.
(2011) report alterations in connectivity associated with neu-
rons derived from schizophrenia. More relevant to ASD,
Pasca et al. (2011) described a phenotype associated with
Timothy syndrome (TS), a syndromic form of autism, linked
to mutations in the CACNA1C gene. Neurons derived from
iPSCs carrying this mutation predictably have a calcium
channel deficit, but more interestingly, they also have a
histogenic deficit; they generate fewer infra-granular callosal
neurons expressing SATB2 and a concomitant increase in
CTIP2 expressing neurons. Interestingly, the authors also
report that their findings were only partly validated in a TS
transgenic mouse model, such that infragranular SATB2 neu-
rons were reduced but numbers of CTIP2 expressing neurons
were unchanged. They note that this could reflect an in vitro
differentiation artefact or more interestingly could represent a
species difference between mouse and human.
Apart from the insight these results provide into Timothy
syndrome, it suggests further that phenotypes associated with
more complex ‘system’ properties of the brain might be
accessible to study in iPSCs. Further encouragement in this
direction is provided by the remarkable capacity of embryonic
and induced pluripotent stem cells to generate in vitro highly
ordered three-dimensional tissue structures driven by largely
intrinsic processes (Sasai 2013). Eiraku et al. have demon-
strated in a manner consistent with the default model of neural
induction that in embryoid bodies (EBs) of a uniform size and
in a minimal media without inhibitors or instructive morpho-
gens, a multilayered cortical-like structure is formed (Eiraku
et al. 2008; Nasu et al. 2012). These structures progress
through an initial neuroepithelial-like stage with a layer of
Pax6+ve cells displaying apico-basal polarity, and sequential-
ly generate neural progenitor cells such as Tbr2+ve/Pax6-ve
transient amplifying cells, followed by Cajal–Rezius cells and
the deep-layer 6 and 5 cortical neurons and finally smaller
numbers of more superficial layer neurons. However, it is
important to note that, although clearly distinguishable layers
are reported to be formed, the usual inside–out pattern of
cortical layers is not established in these structures and more
Fig. 5 SHANK3 staining in
normal human cerebellum 7 μM
paraffin- embedded sections
from human cerebellum were
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superficial layer neurons are under-represented. Despite these
current shortcomings, it is clear that the potential exists to not
only study molecular interactions and cell fate in iPSCs but
that it will become increasingly possible to study four-
dimensional histogenesis in this system in a manner that could
inform and complement developmental studies in vivo.
In summary, we envisage that in vitro models derived from
iPSCs will complement rather than replace animal models of
ASD and other psychiatric disorders in the future. It is antic-
ipated that any disease-associated phenotypes observed in
iPSC-derived assays of ASD will serve to inform experiments
in animal models which will continue to be indispensible in
establishing the crucial link between cellular and molecular
events and behaviour. Although it remains to be seen whether
the iPSC approach will reveal details of the aetiology of ASD
beyond those that emerge from animal models of this disorder,
the relative simplicity and tractability of this approach are
appealing, while the fact that it is human and truly disease-
related give iPSCs a face validity that has been missing from
other cellular models. The approach we have outlined here in
relation to our own studies of SHANK3 can be, and are being,
reproduced in many laboratories with different genetic and
sporadic sources of cells. This first generation of iPSC projects
will undoubtedly have their limitations but may well begin to
cast light on aspects of disease aetiology as yet undiscovered.
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